Classys Reports Nine-Month 2026 Revenue of KRW 275.7 Billion, Up 13% Year over Year; Prepares to Accelerate Growth in 2027 on China Entry, U.S. and Europe Expansion, New Product Launches and Direct-Operations Integration

ملخص مفصل

Nine-month revenue of KRW 275.7 billion and operating profit of KRW 108.1 billion; revenue up 13% year over year China market entry and broader product lineups in the U.S. and…

SEOUL, South Korea, Nov. 13, 2026 /PRNewswire/ -- Classys Inc. (KOSDAQ: 214150), a global medical aesthetics company, announced on November 12 (KST) its results for the third quarter of 2026. On a consolidated basis, nine-month revenue was KRW 275.7 billion and operating profit was KRW 108.1 billion. Revenue increased 13% year over year, while operating profit decreased 9.4%. For the third quarter alone, revenue was KRW 83.0 billion, roughly flat year over year; operating profit was KRW 27.0 billion, for an operating margin of 32.5%.

The third quarter was a period in which near-term pressure on results came together: lower sales in Korea as the Company's core products entered a generational transition, and the shift of LATAM and Japan to direct operations. In LATAM, the Company incurred initial costs to normalize operations at its direct-operations subsidiary, and distribution margin recognized during the sell-through of inventory held before the acquisition of Medsystems (now Classys Brasil) was limited. In Japan, upfront investment related to the transition to direct operations also affected profitability.

The Company views these as temporary integration costs arising from the restructuring of its global business and a product launch cycle. It expects this pressure to ease gradually, and plans to accelerate its recovery and global growth through the stabilization of its direct-operations structure and business expansion in large markets such as China. The Company expects its growing cumulative global unit sales, which have surpassed 50,000 units as of October 2026, along with its accumulated brand, technology and product strengths and its cash-generating capacity, to support this acceleration.

ChinaAhead of its first product approval in China, the Company expects growth momentum in this large market to build. China is becoming a market where companies must obtain formal regulatory approval as approval barriers rise, and demand is expanding mainly for newly approved…

U…

مطلع المقال، مقتطف من PR Newswire. لقراءة المقال كاملًا، افتحه على موقع الناشر.